LIST OF CONTENTS

NUMBER 1

Announcement 1

International Cancer News 3

Editorial

The prognostic value of cathepsin D in breast cancer. A long road to the clinic 7
H. Rochefort

Points of View

The breast screening controversy 9
M. Baum

What do we know on variables influencing clinical decision-making in elderly cancer patients? 12
S. Monfardini

Special Paper

Cathepsin D and breast cancer 15
B.R. Westley and F.E.B. May

Reviews

Palliative endoscopic therapy of rectal carcinoma 25
M. Dohmoto, M. Hünerbein and P.M. Schlag

Role of oxygen free radicals in cancer development 30
D. Dreher and A.F. Junod

Meeting Highlight

On the threshold of success? Report on ECCO8, 29 October–2 November 1995, Paris, France 39
D.C. Purves and I.R. Hart

Clinical Oncology

Selecting high-risk early breast cancer patients: what to add to the number of metastatic nodes? 41
F. Perrone, C. Carlomagno, R. Lauria, M. De Laurentiis, A. Morabito, L. Panico, G. Pettinato, G. Petrella, C. Gallo, A.R. Bianco and S. De Placido

A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines 47
G. Fountzilas, A. Athanassiades, T. Giannakakis, D. Bafaloukos, K. Karakousis, N. Dombros, P. Kosmidis and D. Skarlos

A randomised study comparing granulocyte-colony stimulating factor (G-CSF) with G-CSF plus thymostimulin in the treatment of haematological toxicity in patients with advanced breast cancer after high dose mitoxantrone therapy 52
F. Sanchiz and A. Milla

An economic model to assess the savings from a clinical application of haematopoietic growth factors 57
C.A. Uyl-de Groot, E. Vellenga and F.F.H. Rutten

The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer 63
A. Webb, P. Scott-Mackie, D. Cunningham, A. Norman, J. Andreyev, M. O'Brien and J. Bensted

A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer 69
C. Cotto, J. Berille, P.J. Souquet, R. Riou, B. Croisile, F. Turjman, B. Giroux, J. Brune and V. Trillet-Lenoir

The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853 72
F.C. da Silva, S.D. Fossa, N.K. Aaronson, S. Serbouti, L. Denis, J. Casselman, P. Whelan, J. Hetherington, C. Fava, B. Richards, M.R.G. Robinson and the members of the EORTC Genitourinary Tract Cancer Cooperative Group

Helping cancer patients disclose their concerns 78
P. Maguire, A. Faulkner, K. Booth, C. Elliott and V. Hillier

An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens 82
A. Martoni, B. Angelelli, M. Guaraldi, E. Strocchi and F. Pannuti

MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas 86
U. Stein, R.H. Shoemaker and P.M. Schlag

Paediatric Oncology

Radiolabelled mIBG in the treatment of neuroblastoma 93
M.N. Gaze and T.E. Wheldon

Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation 97
J. Pihkala, U.M. Saarinen, U. Lundström, K. Virtanen, K. Virkola, M.A. Siimes and E. Pesonen

Cancer Epidemiology and Prevention

Quality of prostate cancer data in the Cancer Registry of Norway 104
S. Harvei, S. Tretli and F. Langmark

Cancer of the prostate in Norway 1957–1991—a descriptive study 111
S. Harvei, S. Tretli and F. Langmark

Does age at the last birth affect breast cancer risk? 118
C.-C. Hsieh, H.-W. Chan, M. Lambe, A. Ekbom, H.-O. Adami and D. Trichopoulos

Experimental Oncology

Ectopic vasopressin expression in MMTV-*v-Ha-ras* transgenic mice delays the onset of mammary tumorigenesis 122
K.-F. Chooi, D.A. Carter and D. Murphy

Multiple drug resistance-related messenger RNA expression in archival formalin-fixed paraffin-embedded human breast tumour tissue 128
L. O'Driscoll, S. Kennedy, E. McDermott, P. Kelehan and M. Clynes

Anti-oestrogen stimulation of ERBB2 ectodomain shedding from BT-474 human breast cancer cells with *ERBB2* gene amplification 134
A.M. Wärri, J.J. Isola and P.L. Härkönen

Expression of MHC molecules and ICAM-1 on non-small cell lung carcinomas: association with early lymphatic spread of tumour cells 141
B. Passlick, K. Pantel, B. Kubuschok, M. Angstwurm, A. Neher, O. Thetter, L. Schweiberer and J.R. Izbicki

Inhibitions of protein kinase C and proto-oncogene expressions in NIH 3T3 cells by apigenin 146
Ying-Tang Huang, Min-Liang Kuo, Jer-Yuh Liu, Su-Yu Huang and Jen-Kun Lin

The antimetabolite tiazofurin (TR) inhibits glycoconjugate biosynthesis and invasiveness of tumour cells 152
J. Tímár, J. Tóvári, G. Pogány, A. Ladányi, S. Paku, E. Rásó, J. Bocsi, A. Jeney and K. Lapis

SR8—the establishment and characterisation of a new ovarian carcinoma cell line and xenograft model 160
X. Han, A.J. Papadopoulos, T.A. Jones, D. Sheer and K.S. Raju

Immunostaining of human melanomas by a monoclonal antibody to B700 mouse melanoma antigen 168
X. Xu, N. Azumi, H.G. Skelton, V.J. Hearing and D.M. Gersten

Letters

Adjuvant tamoxifen: 5 year control of dormant disease? 174
O. Merimsky, M. Inbar, F. Kovner and S. Chaitchik

High frequency of urothelial cancers in patients with kidney transplantations for end-stage analgesic nephropathy 175
C. Bokemeyer, W.F. Thon, T. Brunkhorst, M.A. Kuczyk, R. Pichlmayr and V. Kliem

Lonidamine plus epirubicin and cyclophosphamide in advanced breast cancer. A phase II study 176
G. Gardin, C. Barone, O. Nascimben, G. Ianniello, F. Sturba, A. Contu, P. Pronzato and R. Rosso

MSH2 sequence variations and inherited colorectal cancer susceptibility 178
N.J. Froggatt, J.A. Joyce, D.G.R. Evans, P.W. Lunt, D.J. Koch, B.J. Ponder and E.R. Maher

Chemotherapy with doxorubicin, etoposide and cyclophosphamide (DEC) in ovarian cancer persistent after platinum-based treatment 178
G. Zanetta, S. Lo Monico, A. Gabriele, D. Miceli and C. Mangioni

Upper age limit for cervical cancer screening 180
S. Cecchini, A. Iossa and S. Ciatto

Dacarbazine, vincristine, bleomycin and lomustine plus natural interferon-alpha for metastatic melanoma 180
U. Reinhold, Th. Bruske and H.W. Kreysel

Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group 181
V. Urosevic, Ph. Chollet, A. Adenis, J. Chauvergne, P. Fargeot, H. Roche, P. Kerbrat, M.A. Lentz, P. Fumoleau and B. Chevallier

Octreotide treatment of chemotherapy-induced diarrhoea 182
P. Ginopoulos, Th. Papagiannis, Ch. Safridi, F. Karvelas, K. Spyropoulos, Th. Papadas and Ch. Gogos

Corrections 185

Calendar of Forthcoming Meetings 187

Information for Authors I

NUMBER 2

International Cancer News 195

Editorial

Radon and childhood cancers 201
L. Parker and A.W. Craft

Point of View

High-dose chemotherapy for breast cancer 205
R.C.F. Leonard

Special Paper

Current and future trends in the multidisciplinary approach for high-risk breast cancer. The experience of the Milan Cancer Institute 209
G. Bonadonna

Clinical Oncology

Expression of p53 protein as a prognostic factor in patients with gastric cancer 215
M. Victorzon, S. Nordling, C. Haglund, J. Lundin and P.J. Roberts

Prognostic value of serum alpha-1-antitrypsin in hepatocellular carcinoma 221
M. Pirisi, C. Fabris, G. Soardo, P. Toniutto, D. Vitulli and E. Bartoli

Evaluation of antitumour effects of docetaxel (Taxotere®) on human gastric cancers *in vitro* and *in vivo* 226
M. Tanaka, T. Obata and T. Sasaki

Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients 231
F. Revillion, M. Hebbar, J. Bonneterre and J.P. Peyrat

Postoperative adjuvant randomised trial comparing chemo-endocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemo-endocrine Therapy for Breast Cancer (ACETBC) of Japan 235
T. Morimoto, M. Ogawa, K. Orita, K. Sugimachi, T. Toge, K. Dohi, Y. Nomura, Y. Monden and N. Ogawa

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study 243
U. Gatzemeier, F.A. Shepherd, T. Le Chevalier, P. Weynants, B. Cottier, H.J.M. Groen, R. Rosso, K. Mattson, H. Cortes-Funes, M. Tonato, R.L. Burkes, M. Gottfried and M. Voi

Concurrent radiotherapy and continuous ambulatory infusion 5-fluorouracil in advanced head and neck cancer 249
I.N. Olver, P.G. Hughes, J.G. Smith, K. Narayan and J.F. Bishop

Well-differentiated papillary mesothelioma of the peritoneum: a separate entity 255
K. Hoekman, G. Tognon, E.K.J. Risse, C.A. Bloemsma and J.B. Vermorken

Multiple tumour marker assays in advanced cervical cancer: relationship to chemotherapy response and clinical outcome 259
G. Scambia, P. Benedetti Panici, E. Foti, G. Ferrandina, F.P.G. Leone, M. Marciano and S. Mancuso

Identification of lymph node metastases by use of polymerase chain reaction (PCR) in melanoma patients 264
M. Schwürzer-Voit, T.M. Proebstle and W. Sterry

The importance of a multidisciplinary group in the treatment of soft tissue sarcomas 269
T. Wiklund, R. Huuhtanen, C. Blomqvist, E. Tukiainen, M. Virolainen, P. Virkkunen, S. Asko-Seljavaara, J.M. Björkenheim and I. Elomaa

Spiritual healing among Norwegian hospitalised cancer patients and patients' religious needs and preferences of pastoral services 274
T. Risberg, E. Wist, S. Kaasa, E. Lund and J. Norum

Paediatric Oncology

Radon in Devon and Cornwall and paediatric malignancies 282
R. Thorne, N.K. Foreman and M.G. Mott

Small influence of parental educational level on the survival of children with leukaemia in The Netherlands between 1973 and 1979 286
J.W.W. Coebergh, A. van der Does-van den Berg, W.C.J. Hop, F. van Weerden, J.A. Rammeloo, H.A. van Steensel, E.R. van Wering and W.A. Kamps

Information about diagnosis and prognosis related to anxiety and depression in children with cancer aged 8–16 years 290
B.F. Last and A.M.H. van Veldhuizen

Cancer Epidemiology and Prevention

Survival for colon and rectal cancer in a population-based cancer registry 295
L. Roncucci, R. Fante, L. Losi, C. Di Gregorio, A. Micheli, P. Benatti, N. Madenis, D. Ganazzi, M.T. Cassinadri, P. Lauriola and M. Ponz de Leon

The role of reproductive and menstrual factors in cancer of the breast before and after menopause 303
R. Talamini, S. Franceschi, C. La Vecchia, E. Negri, L. Borsa, M. Montella, F. Falcini, E. Conti and C. Rossi

Experimental Oncology

Lack of effect of corticosteroids and tamoxifen on suramin protein binding and *in vitro* activity 311
D.L. Driscoll, R.W. Steinkampf, L.J. Paradiso, C.D. Kowal and W.D. Klohs

Red blood cell polyamines, anaemia and tumour growth in the rat 316
V. Quemener, J.Y. Bansard, M. Delamaire, S. Roth, R. Havouis, D. Desury and J.-Ph. Moulinoux

Reversion of UVC-induced tumorigenic human hybrid cells to the non-tumorigenic phenotype 322
C. Sun, R. J. Antonionio and J. L. Redpath

Photodynamic effects of 5-aminolevulinic acid-induced porphyrin on human bladder carcinoma cells *in vitro* 328
R. Riesenberg, C. Fuchs and M. Kriegmair

Frequent *TP*53 gene alterations (mutation, allelic loss, nuclear accumulation) in primary non-small cell lung Cancer 335
R. Shipman, P. Schraml, M. Colombi, G. Raefle, P. Dalquen and C. Ludwig

Effect of tyrphostin combined with a substance P related antagonist on small cell lung cancer cell growth *in vitro* 342
M.J. Seckl and E. Rozengurt

Newly established MST-1 tumour cell line and tumour-infiltrating lymphocyte culture from a patient with soft tissue melanoma (clear cell sarcoma) and their potential applications to patient immunotherapy 346
S.-K. Liao, Y.-P. Perng, L.-A. Lee, K.S.S. Chang, G.-M. Lai, E. Wong and Y.-S. Ho

Correlations of Ki-67 and PCNA to DNA ploidy, S-phase fraction and survival in uveal melanoma 357
M. Karlsson, B. Boeryd, J. Carstensen, B. Frånlund, B. Gustafsson, B. Kågedal, X.-F. Sun and S. Wingren

Short Communications

Epithelial tumour cells in bone marrow of patients with pancreatic carcinoma detected by immunocytochemical staining 363
S. Thorban, J.D. Roder, K. Pantel and J.R. Siewert

Retinoic acid concentrations in patients with squamous cell carcinoma of the head and neck 366
P. Wahlberg and G. Fex

Letters

5-Fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure? 368
T. Lieutaud, E. Brain, D. Golgran-Toledano, F. Vincent, E. Cvitkovic, B. Leclercq and B. Escudier

Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta 369
P. Beuzeboc, J.-Y. Pierga, D. Stoppa-Lyonnet, M.C. Etienne, G. Milano and P. Pouillart

Vinorelbine/5-FU combination in metastatic breast cancer chemotherapy. A retrospective study of 63 cases 370
L. Cany, C. Toulouse, A. Ravaud, M. Durand and L. Mauriac

Studies of HLA-A and DR locus deletions in human liver cancer cell lines by PCR 371
Qing Li, S. H. Chan and E. C. Ren

Adenocarcinoma of the eccrine sweat gland: response to both combination chemotherapy and local field irradiation 372
W.C. Mertens, D.T. Shum and J.A. Gilchrist

Chemotherapy-induced onycholysis 374
A. Makris, P. Mortimer and T.J. Powles

Prevention of second primary tumours with a second generation retinoid in squamous cell carcinoma of oral cavity and oropharynx: long term follow-up 375
M. Bolla, A. Laplanche, R. Lefur, J. Ton Van, C. Domenge, J.-L. Lefebvre and B. Luboinski for the French Study Group on Head and Neck Tumour (GETTEC) France

"It feels better"—measuring clinical benefit 376
D.D. Von Hoff

Calendar of Forthcoming Meetings 379

Information for Authors I

NUMBER 3

International Cancer News 387

Editorials

Cancer genetics clinics 391
D.G.R. Evans, J. Cuzick and A. Howell

New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity 393
M. Castiglione-Gertsch

Point of View

Prebiopsy neo-adjuvant endocrine therapy for breast cancer to prevent post-surgery trauma-induced growth factor and immune-suppression mediated tumour progression 396
R.T.D. Oliver, J. Tobias and C. Gallagher

Special Paper

Cancer genetics clinics: target population and consultees' expectations 398
C. Julian-Reynier, F. Eisinger, F. Chabal, Y. Aurran, C. Noguès, P. Vennin, Y.-J. Bignon, M. Machelard-Roumagnac, C. Maugard-Louboutin, D. Serin, S. Versini, M. Mercuri and H. Sobol

Clinical Oncology

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer 404
W. Jonat, A. Howell, C. Blomqvist, W. Eiermann, G. Winblad, C. Tyrrell, L. Mauriac, H. Roche, S. Lundgren, R. Hellmund and M. Azab on behalf of the ARIMIDEX Study Group

Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer 413
R.A. McClelland, J.M.W. Gee, A.B. Francis, J.F.R. Robertson, R.W. Blamey, A.E. Wakeling and R.I. Nicholson

Prognosis of patients with breast cancers up to 1 cm in diameter 417
I.S. Fentiman, D. Hyland, M.A. Chaudary and W.M. Gregory

Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic Co-operative Oncology Group study 421
D.V. Skarlos, G. Aravantinos, P. Kosmidis, N. Pavlidis, K. Gennatas, M. Beer, N. Mylonakis, P. Makrantonakis, G. Klouvas, S. Karpathios, H. Linardou, C. Konstantaras and G. Fountzilas

Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer 429
E. Roca, E. Pennella, M. Sardi, S. Carraro, M. Barugel, C. Milano, A. Fiorini, R. Giglio, G. Gonzalez, R. Kneitschel, E. Aman, A. Jarentchuk, C. Blajman, J. Nadal, M.T. Santarelli and A. Navigante

Prognostic value of resection-line involvement in patients undergoing curative resections for gastric cancer 433
I. Songun, J.J. Bonenkamp, J. Hermans, J.H.J.M. van Krieken, C.J.H. van de Velde and Co-operating Investigators of the Dutch Gastric Cancer Trial

Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung 438
J.M. Beith, S.J. Clarke, R.L. Woods, D.R. Bell and J.A. Levi

Superficial bladder cancer: study of the proliferative nuclear fraction as a prognostic factor 444
E. Blasco-Olaetxea, L. Belloso and J. Garcia-Tamayo

Tumour necrosis factor (TNF) soluble receptors in malignant melanoma: correlation with soluble ICAM-1 levels 447
J. Viac, C. Vincent, S. Palacio, D. Schmitt and A. Claudy

Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? 450
A.T.M. van Holten-Verzantvoort, J. Hermans, L.V.A.M. Beex, G. Blijham, F.J. Cleton, B.C.F. van Eck-Smit, H.P. Sleeboom and S.E. Papapoulos

Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French Cancer Centre multicentric study 455
A. Iliadis, M.-C. Launay-Iliadis, C. Lucas, R. Fety, F. Lokiec, B. Tranchand and G. Milano

Paediatric Oncology

The role of bone scintigraphy in the follow-up of osteogenic sarcoma 461
D. Körholz, I. Wirtz, H. Vosberg, W. Rüther, H. Jürgens and U. Göbel

Renal function after unilateral nephrectomy for Wilms' tumour: the influence of radiation therapy 465
S.S.N. de Graaf, H. van Gent, W.Ch.C. Reitsma-Bierens, W.H.J. van Luyk, W.V. Dolsma and A. Postma

Cancer Epidemiology and Prevention

The follicular non-Hodgkin's lymphomas—I. The possibility of cure 470
J.W. Denham, E. Denham, K.B. Dear and G.V. Hudson

The follicular non-Hodgkin's lymphomas—II. Prognostic factors: what do they mean? 480
J.W. Denham, E. Denham, K.B. Dear and G.V. Hudson

Experimental Oncology

C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas 491
J. Elnatan, H.-S. Goh and D.R. Smith

Anti-idiotypic response to antigrowth factor receptor monoclonal antibodies 498
E. Tosi, O. Valota, S. Canevari, E. Adobati, P. Casalini, P. Perez and M.I. Colnaghi

Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB 506
E.A.M. Fleer, D. Berkovic, U. Grunwald and W. Hiddemann

TTF-1 gene expression in human lung tumours 512
D. Fabbro, C. Di Loreto, O. Stamerra, C. Alberto Beltrami, R. Lonigro and G. Damante

Expression of FGFR2 BEK and K-SAM mRNA variants in normal and malignant human breast 518
Y.A. Luqmani, G.S. Bansal, C. Mortimer, L. Buluwela and R.C. Coombes

Intracellular localisation of suramin, an anticancer drug, in human colon adenocarcinoma cells: a study by quantitative autoradiography 525
S. Baghdiguian, J.L. Boudier, J.A. Boudier and J. Fantini

Transfection of wild-type *TP53* induces differentiation in human gingival carcinoma cells 533
R. Takahashi, T. Inagaki, S. Matsuwari, M. Fujioka, S. Maeda, N. Ijuhin, H. Haga, T. Koh, K. Shimada and H. Saya

Effect of intracellular acidity and ionomycin on apoptosis in HL-60 cells 540
H.J. Park, C.M. Makepeace, J.C. Lyons and C.W. Song

Short Communications

Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer 547
U. Klaassen, H. Wilke, D. Strumberg, W. Eberhardt, M. Korn and S. Seeber

Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin 550
S. Sleijfer, T.W. van der Mark, H. Schraffordt Koops and N.H. Mulder

Letters

Autologous bone marrow transplantation for uterine sarcoma. Case report 553
F. Recchia, L. Ginaldi, S. Discepoli, M. De Martinis, F. Coloni and D. Quaglino

Skin lesions and G-CSF in patients with malignant diseases. Malignancy or cutaneous side-effect? 554
A. Loraas, S.D. Fosså, S. Franzen, G. Sæter and L. Rode

Herpesvirus-like DNA sequences selectively cluster with body cavity-based lymphomas throughout the spectrum of AIDS-related lymphomatous effusions 555
A. Carbone, U. Tirelli, A. Gloghini, C. Pastore, E. Vaccher and G. Gaidano

Magnesium supplements with cisplatin chemotherapy 556
F.J. Lofts, T.R.J. Evans, R. Wastnage and J.L. Mansi

Calendar of Forthcoming Meetings 559

Information for Authors I

NUMBER 4

International Cancer News — 567

Editorials

Significant trends in cancer in the elderly — 569
J.W.W. Coebergh

Chemotherapy for ovarian germ cell tumours — 572
M. Kaufmann and G.v. Minckwitz

Point of View

Drug evaluation and approval in the European Community — 574
M. Marty

Special Paper

New endocrine therapies for breast cancer — 576
A. Howell, S. Downey and E. Anderson

Review

Magnetic resonance imaging: present position and future prospects — 589
W.L. Curati and G.M. Bydder

Clinical Oncology

Chemotherapy for ovarian germ cell tumours — 593
M. Bower, K. Fife, L. Holden, F.J. Paradinas, G.J.S. Rustin and E.S. Newlands

Mutant p53 protein as a predictor of survival in endometrial carcinoma — 598
P. Strang, B. Nordström, S. Nilsson, R. Bergström and B. Tribukait

Reproducibility of histological diagnosis of breast lesions: results of a panel in Italy — 603
D. Palli, M. Galli, S. Bianchi, G. Bussolati, S. Di Palma, V. Eusebi, M. Gambacorta and M. Rosselli Del Turco

Inadequacy of iridium implant as sole radiation treatment for operable breast cancer — 608
I.S. Fentiman, C. Poole, D. Tong, P.J. Winter, W.M. Gregory, H.M.O. Mayles, P. Turner, M.A. Chaudary and R.D. Rubens

An image analysis study of DNA content in early colorectal cancer — 612
E.W. Kay, H.E. Mulcahy, B. Curran, D.P. O'Donoghue and M. Leader

Isolated axillary recurrences after conservative treatment of breast cancer — 617
C. Renolleau, P. Merviel, K.B. Clough, B. Asselain, F. Campana and J.C. Durand

The management of retroperitoneal soft tissue sarcomas — 622
M.P. Jenkins, J.C. Alvaranga and J.M. Thomas

Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia 627
K. Jung, M. Lein, S. Weiss, D. Schnorr, W. Henke and S. Loening

Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF 631
P.A. Ford, S.G. Arbuck, C. Minniti, L.L. Miller, D. DeMaria and P.J. O'Dwyer

Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55 900) in patients with recurrent malignant gliomas 636
G. Stragliotto, F. Vega, P. Stasiecki, P. Gropp, M. Poisson and J.-Y. Delattre

Paediatric Oncology

Commentary 641
Multidrug resistance reversal in childhood malignancies—potential for a real step forward?
C.R. Pinkerton

N-MYC amplification, loss of heterozygosity on the short arm of chromosome 1 and DNA ploidy in retinoblastoma 645
F. Doz, M. Peter, G. Schleiermacher, P. Vielh, P. Validire, M. Putterman, V. Blanquet, L. Desjardins, J.-L. Dufier, J.-M. Zucker, V. Mosseri, G. Thomas, H. Magdelénat and O. Delattre

Letter 650
Kaposi's sarcoma in children with AIDS in Europe and the United States
D. Serraino and S. Franceschi

Cancer Epidemiology and Prevention

Worldwide trends in cancer mortality in the elderly, 1955–1992 652
F. Levi, C. La Vecchia, F. Lucchini and E. Negri

Dietary risk factors for renal cell carcinoma in Denmark 673
A. Mellemgaard, J.K. McLaughlin, K. Overvad and J.H. Olsen

Multiple primary cancers and estimation of the incidence rates and trends 683
K. Filali, G. Hédelin, P. Schaffer, J. Estève, P. Arveux, C. Bouchardy, C. Exbrayat, J. Faivre, F. Lévi, J. Macé-Lesech, D. Pottier and J. Torhorst

Experimental Oncology

Direct gene transfer of a plasmid carrying the herpes simplex virus-thymidine kinase gene (HSV-TK) in transplanted murine melanoma: *in vivo* study 691
C. Soubrane, R. Mouawad, O. Rixe, V. Calvez, A. Ghoumari, O. Verola, M. Weil and D. Khayat

Androgen-like and anti-androgen-like effects of antiprogestins in human mammary cancer cells 696
R. Hackenberg, K. Hannig, S. Beck, P. Schmidt-Rhode, A. Scholz and K.-D. Schulz

In vitro anti-proliferative and anti-invasive role of amino-terminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells 702
C. Luparello and M. Del Rosso

From amsacrine to DACA (N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives 708
G.J. Finlay, J.-F. Riou and B.C. Baguley

Characterisation of platelet aggregation induced by PC-3 human prostate adenocarcinoma cells and inhibited by venom peptides, trigramin and rhodostomin 715
M.W. Swaim, H.-S. Chiang and T.-F. Huang

Application of competition theory to tumour growth: implications for tumour biology and treatment 722
R.A. Gatenby

Short Communications

The invisible colours of melanoma. A telespectrophotometric diagnostic approach on pigmented skin lesions 727
A. Bono, S. Tomatis, C. Bartoli, N. Cascinelli, C. Clemente, C. Cupeta and R. Marchesini

Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma 730
M. Guida, A. Latorre, A. Mastria and M. De Lena

Letters

Increased risk of malignancy for patients with chronic granulomatous disease and its possible link to the pathogenesis of cancer 734
E.A.M. Weel, W.K. Redekop and R.S. Weening

Home therapy with autologous tumour-infiltrating lymphocytes and subcutaneous interleukin-2 in metastatic melanoma 735
M.-H. Tessier, M.-C. Pandolfino, F. Jotereau, D. Boudart, P. Litoux and B. Dréno

Beneficial effects of octreotide in a patient with a metastatic paraganglioma 737
F. Tenenbaum, M. Schlumberger, J. Lumbroso and C. Parmentier

Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment with irinotecan (CPT-11) 737
M. Boisseau, R. Bugat and M. Mahjoubi

Major interactions between radiation therapy and systemic sclerosis: is there an optimal treatment? 738
S. Delanian, C. Maulard-Durdux, J.-L. Lefaix and M. Housset

Calendar of Forthcoming Meetings 741

Information for Authors I

NUMBER 5

International Cancer News 749

Editorial

Defining quality of life 753
S.R. Cohen, B.M. Mount and N. MacDonald

Special Paper

Measuring the meaning of life for patients with incurable cancer: the Life Evaluation Questionnaire (LEQ) 755
P. Salmon, F. Manzi and R.M. Valori

Review

Studies of cancer in migrants: rationale and methodology 761
D.M. Parkin and M. Khlat

Clinical Oncology

Prophylactic cranial irradiation in limited stage small cell lung cancer: survival benefit in patients with favourable characteristics 772
E. Work, S.M. Bentzen, O.S. Nielsen, K. Fode, W. Michalski, T. Palshof and The Aarhus Lung Cancer Group

Detection of bone marrow metastases in small cell lung cancer. Comparison of magnetic resonance imaging with standard methods 779
M.M.H. Hochstenbag, G. Snoep, N.A.M. Cobben, A.M.W.J. Schols, F.B.J.M. Thunnissen, E.F.M. Wouters and G.P.M. ten Velde

Detection of human papillomavirus DNA in laryngeal squamous cell carcinoma by polymerase chain reaction 783
G. Almadori, G. Cadoni, P. Cattani, P. Posteraro, E. Scarano, F. Ottaviani, G. Paludetti and M. Maurizi

Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects 789
J. Geisler, D.C. Johannessen, G. Anker and P.E. Lønning

Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay 793
M. Fernö, P.-O. Bendahl, Å. Borg, J. Brundell, L. Hirschberg, H. Olsson and D. Killander

Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis 802
G. Flamini, G. Curigliano, C. Ratto, A. Astone, G. Ferretti, P. Nucera, L. Sofo, A. Sgambato, A. Boninsegna, F. Crucitti and A. Cittadini

A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy 807
B. Audhuy, P. Cappelaere, M. Martin, A. Cervantes, M. Fabbro, A. Rivière, D. Khayat, H. Bleiberg, M. Faraldi and N. Claverie on behalf of the European Dolasetron Comparative Study Group

Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial 814
C. Viscoli, E. Castagnola, M.T. Van Lint, C. Moroni, A. Garaventa, M.R. Rossi, R. Fanci, F. Menichetti, D. Caselli, M. Giacchino and M. Congiu

Paediatric Oncology

Response of previously untreated metastatic rhabdomyosarcoma to combination chemotherapy with carboplatin, epirubicin and vincristine 821
E. Frascella, K. Pritchard-Jones, S. Modak, A.F. Mancini, M. Carli and C.R. Pinkerton on behalf of the MMT Working Party of the International Society of Paediatric Oncologists

Cardiac transplantation in childhood cancer survivors in Great Britain 826
G. Levitt, K. Bunch, C.A. Rogers and B. Whitehead

Cancer Epidemiology and Prevention

Substantial variation in therapy for colorectal cancer across Europe: EUROCARE analysis of cancer registry data for 1987 831
G. Gatta, M. Sant, J.W. Coebergh, T. Hakulinen and the EUROCARE Working Group

Risk factors for invasive cervix cancer in young women 836
J. Cuzick, P. Sasieni and A. Singer

Experimental Oncology

Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D_3 and the vitamin D_3 analogue EB1089 842
T. Vink-van Wijngaarden, H.A.P. Pols, C.J. Buurman, J.C. Birkenhäger and J.P.T.M. van Leeuwen

Differential responsiveness of proliferation and cytokeratin release to stripped serum and oestrogen in the human breast cancer cell line, MCF-7 849
T. Tedone, M. Correale, A. Paradiso and S.J. Reshkin

Modulation of P-glycoprotein mediated drug accumulation in multidrug resistant CCRF VCR-1000 cells by chemosensitisers 857
R. Boer, V. Gekeler, W.-R. Ulrich, P. Zimmermann, W. Ise, A. Schödl and S. Haas

Serum can inhibit reversal of multidrug resistance by chemosensitisers 862
M. Lehnert, R. de Giuli, K. Kunke, S. Emerson, W.S. Dalton and S.E. Salmon

The effect of exogenous gangliosides on matrix metalloproteinase secretion by human glioma cells *in vitro* 868
S.L. Maidment, A. Merzak, S. Koochekpour, H.K. Rooprai, G.J. Rucklidge and G.J. Pilkington

Prevalence of serum antibodies to synthetic peptides to HPV16 epitopes among Indian women with cervical neoplasia 872
B.K. Sharma, A. Ray and N.S. Murthy

Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin 877
G. Scambia, R. De Vincenzo, F.O. Ranelletti, P. Benedetti Panici, G. Ferrandina, G. D'Agostino, A. Fattorossi, E. Bombardelli and S. Mancuso

Cytotoxic activity of calcein acetoxymethyl ester (Calcein/AM) on primary cultures of human haematological and solid tumours 883
B. Jonsson, G. Liminga, K. Csoka, H. Fridborg, S. Dhar, P. Nygren and R. Larsson

Short Communications

Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8°C whole body hyperthermia in patients with refractory sarcoma 888
G.J. Wiedemann, H.I. Robins, S. Gutsche, M. Mentzel, M. Deeken, D.M. Katschinski, S. Eleftheriadis, R. Crahé, C. Weiss, B. Storer and T. Wagner

Contribution of cervical ultrasound and ultrasound fine-needle aspiration biopsy to the staging of thoracic oesophageal carcinoma 893
S. Bonvalot, N. Bouvard, P. Lothaire, J. Maurel, F. Galateau, P. Ségol and M. Gignoux

Loss of heterozygosity at the *DCC* gene locus is not crucial for the acquisition of metastatic potential in oesophageal squamous cell carcinoma 896
C. Maesawa, G. Tamura, S. Ogasawara, Y. Suzuki, K. Sakata, J. Sugimura, S. Nishizuka, N. Sato, K. Ishida, K. Saito and R. Satodate

Letters

Phase II trial of epirubicin at standard dose in relapsed ovarian cancer 899
I. Peláez, A.J. Lacave, I. Palacio, E. Alvarez, J.F. Cueva, I. Muñiz, F. Arranz and J. Fra

Follow-up for stage 1 teratoma surveillance patients 900
F. Lander, S. MacBride, L. Samuel, G. Howard and M. Cornbleet

Single agent paclitaxel in advanced squamous cell head and neck carcinoma 901
V. Gebbia, A. Testa, G. Cannata and N. Gebbia

Primary Ki-1 lymphoma and the aetiology of B symptoms 902
N. O'Rourke, S. Kelly, T. Vulliamy and P. Price

Correction 904

Calendar of Forthcoming Meetings 905

Information for Authors I

NUMBER 6

Special Issue: Multidrug Resistance in Cancer

Foreword 911

Clinical multidrug resistance in cancer: a multifactorial problem 912
M. Lehnert

Apoptosis and chemotherapy resistance 921
J.A. Hickman

P-glycoprotein—a mediator of multidrug resistance in tumour cells 927
U.A. Germann

Biology of the multidrug resistance-associated protein, MRP 945
D.W. Loe, R.G. Deeley and S.P.C. Cole

Antitopoisomerase drug action and resistance 958
J.L. Nitiss and W.T. Beck

Glutathione and related enzymes in multidrug resistance 967
M.L. O'Brien and K.D. Tew

Major vault protein LRP-related multidrug resistance 979
M.A. Izquierdo, G.L. Scheffer, M.J. Flens, A.B. Schroeijers, P. van der Valk and R. J. Scheper

What have we learnt thus far from mice with disrupted P-glycoprotein genes? 985
P. Borst and A.H. Schinkel

Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers 991
J.M. Ford

Experimental modulation of MRP (multidrug resistance-associated protein)-mediated resistance 1002
P.R. Twentyman and C.H.M. Versantvoort

Oligonucleotide modulation of multidrug resistance 1010
D.Y. Bouffard, T. Ohkawa, H. Kijima, A. Irie, T. Suzuki, L.D. Curcio, P. S. Holm, A. Sassani and K.J. Scanlon

Transfer of the *MDR1* gene into haematopoietic cells 1019
M. Baudard, I. Pastan and M.M. Gottesman

How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein 1024
H.J. Broxterman, J. Lankelma and H.M. Pinedo

MDR1/P-glycoprotein in haematological neoplasms 1034
J.-P. Marie, D.-C. Zhou, S. Gurbuxani, O. Legrand and R. Zittoun

MDR1 gene expression in solid tumours 1039
L.J. Goldstein

Diagnosis and reversal of multidrug resistance in paediatric cancers 1051
H.S.L. Chan, T.M. Grogan, G. DeBoer, G. Haddad, B.L. Gallie and V. Ling

Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies 1062
P. Sonneveld

Clinical trials of P-glycoprotein reversal in solid tumours 1070
D.R. Ferry, H. Traunecker and D.J. Kerr

Pharmacological considerations in the modulation of multidrug resistance 1082
G.A. Fisher, B.L. Lum, J. Hausdorff and B.I. Sikic

Information for Authors I

NUMBER 7

International Cancer News 1089

Editorials

PSA and prostate cancer diagnosis 1097
P. Savage and J. Waxman

Ifosfamide and paediatrics: should this marriage be saved? 1100
R.B. Womer

Special Paper

Accuracy of admission and clinical diagnosis of tumours as revealed by 2000 autopsies 1102
B. Szende, G. Kendrey, K. Lapis, F.J.C. Roe and P.N. Lee

Reviews

Carcinoid of the pancreas: clinical characteristics and morphological features 1109
C.A. Maurer, H.-U. Baer, T.H. Dyong, E. Mueller-Garamvoelgyi, H. Friess, C. Ruchti, J.-C. Reubi and M.W. Büchler

Locoregional chemotherapy for adjuvant treatment of colorectal adenocarcinoma 1117
C. Penna and B. Nordlinger

Meeting Highlight

Second International Symposium on Febrile Neutropenia, Brussels, 14–16 December 1995 1123
U. Hess

Clinical Oncology

Value of PSA (prostate-specific antigen) in the detection of prostate cancer in patients with urological symptoms. Results of a multicentre study 1125
X. Filella, R. Molina, A.M. Ballesta, M.J. Gil, C. Allepuz, L.A. Rioja and the Cooperative Group for the Diagnosis of Prostate Cancer

Genitourinary group phase II study of chemotherapy in stage T3–4 N0–X M0 transitional cell cancer of the bladder: prognostic factor analysis 1129
T.A.W. Splinter, M. Pavone-Macaluso, D. Jacqmin, J.T. Roberts, P. Carpentier, M. de Pauw and T. Sahmoud

Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution 1135
G. Buccheri, D. Ferrigno and M. Tamburini

Effect of home care on the place of death of advanced cancer patients 1142
F. De Conno, A. Caraceni, L. Groff, C. Brunelli, I. Donati, M. Tamburini and V. Ventafridda

Immunohistochemical evaluation of multiple biological markers in ductal carcinoma *in situ* of the breast 1148
T. Perin, V. Canzonieri, S. Massarut, E. Bidoli, C. Rossi, M. Roncadin and A. Carbone

Pre-operative serum levels of CA 242 and CEA predict outcome in colorectal cancer 1156
M. Carpelan-Holmström, C. Haglund, J. Lundin, H. Järvinen and P. Roberts

Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation 1162
E. Souêtre, W.Qing and P.F. Pénelaud

Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma 1166
I. Elomaa, L. Risteli, M. Laakso, R. Lahtinen, P. Virkkunen and J. Risteli for the Finnish Leukaemia Group

An open phase I study to assess the biological effects of a continuous intravenous infusion of interleukin-3 followed by granulocyte macrophage-colony stimulating factor 1171
S. Bretti, M.H. Gilleece, A. Kamthan, L. Fitzsimmons, F. Hicks, M. Rowlands, P. Bishop, A.-M. Picardo, T.M. Dexter and J.H. Scarffe

Paediatric Oncology

Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics 1179
A.V. Boddy, M. English, A.D.J. Pearson, J.R. Idle and R. Skinner

Review
Monitoring chemotherapy-induced hearing loss in children 1185
S.C. Bellman

Cancer Epidemiology and Prevention

An ecological study of cancer incidence and radon levels in South West England 1189
D.J. Etherington, D.F.H. Pheby and F.I. Bray

Variations in the screening history and appropriateness of management of cervical cancer in South East England 1198
C.D.A. Wolfe, K. Tilling, H.M. Bourne and K.S. Raju

Experimental Oncology

DNA amplification on chromosome 3q26.1–q26.3 in squamous cell carcinoma of the lung detected by reverse chromosome painting 1205
N. Brass, I. Ukena, K. Remberger, U. Mack, G.W. Sybrecht and E.U. Meese

Prognostic and aetiological relevance of 8-hydroxyguanosine in human breast carcinogenesis 1209
J. Musarrat, J. Arezina-Wilson and A.A. Wani

Elevated serum E-selectin in patients with liver metastases of colorectal cancer 1215
B.M. Wittig, H. Kaulen, R. Thees, C. Schmitt, P. Knolle, J. Stock, K.H. Meyer zum Büschenfelde and W. Dippold

Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: *in vitro* synergistic cytotoxicity and DNA-induced strand-breaks 1219
M. Andreuccetti, G. Allegrini, A. Antonuzzo, G. Malvaldi, P.F. Conte, R. Danesi, M. Del Tacca and A. Falcone

The activity and expression of thymidine phosphorylase in human solid tumours 1227
Y. Takebayashi, K. Yamada, K. Miyadera, T. Sumizawa, T. Furukawa, F. Kinoshita, D. Aoki, H. Okumura, Y. Yamada, S.-i. Akiyama and T. Aikou

Phenotypic and functional characterisation of tumour-infiltrating lymphocytes derived from thyroid tumours 1233
R.S. Lee, M. Schlumberger, B. Caillou, F. Pages, W.H. Fridman and E. Tartour

[^{211}At]Methylene blue for targeted radiotherapy of human melanoma xenografts: dose fractionation in the treatment of cutaneous tumours 1240
E.M. Link, R.N. Carpenter and G. Hansen

Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways 1248
J.R.W. Masters, R. Thomas, A.G. Hall, L. Hogarth, E.C. Matheson, A.R. Cattan and H. Lohrer

Short Communications

Phase II trial of *N*-(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon-α-2b in patients with advanced gastric carcinoma 1254
S. Wadler, B. Gleissner, R.U. Hilgenfeld, E. Thiel, H. Haynes, R. Kaleya, A. Rozenblit and E.-D. Kreuser

Long-term positron emission tomography evaluation of slowly progressive gliomas 1257
K. Mineura, T. Sasajima, M. Kowada, T. Ogawa, J. Hatazawa and K. Uemura

Letters

Bronchioloalveolar carcinoma presenting aerogenous metastasis to the upper airway 1261
N. Hidaka, Y. Hidaka, Y. Tajima, I. Sugano and K. Nagao

Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease 1262
F. Tenenbaum, C. Corone, M. Schlumberger and C. Parmentier

Increasing the dose intensity of chemotherapy by means of granulocyte-colony stimulating factor (G-CSF) support in the treatment of small cell lung cancer (SCLC) 1263
D.J. Girling, N. Thatcher, P.I. Clark and R.J. Stephens

Correction 1264

Calendar of Forthcoming Meetings 1265

Information for Authors I

NUMBER 8

Message from the Editor-in-Chief 1271

International Cancer News 1273

Editorials

Multiple primary cancers in population-based cancer registries 1279
M.M. Hawkins

Health-related quality of life, cancer and health care 1281
M.E.M. Jenney

Review

Cancer: a challenge for control theory and computer modelling 1283
W. Düchting, W. Ulmer and T. Ginsberg

Point of View

Obesity, social class and Western diet: a link to breast cancer prognosis 1293
B.A. Stoll

Special Paper

Continuing Medical Education in Oncology in Europe 1296
J.P. Armand, A. Costa, J. Geraghty, N. O'Higgins, P.J. Broe, L. Holmberg, D.Th. Sleijfer and J. de Toeuf

Meeting Highlight

Cancer research in the European Community—report from a meeting in Stockholm in 1995 1300
G. Gahrton, A. Graessmann, F. Meunier, M. Schmitt, J.J.M. Van Dongen and S.S. Baig

Clinical Oncology

Sex as a prognostic factor in gastric cancer 1303
A. Maguire, M. Porta, J.M. Sanz-Anquela, I. Ruano, N. Malats and J.L. Piñol

Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study 1310
D.J.Th. Wagener, W.J. Hoogenraad, Ph. Rougier, A. Lusinchi, B.G. Taal, C.H.N. Veenhof, A. de Graeff, T. Conroy, D. Curran, T. Sahmoud and J. Wils

Feasibility of escalating daily doses of cisplatin in combination with accelerated radiotherapy in non-small cell lung cancer 1314
A.L.J. Schuster-Uitterhoeve, P.J.M. van de Vaart, C.C.E. Schaake-Koning, J. Benraadt, M.G.J. Koolen, D. González González and H. Bartelink

Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer 1320
P. Sagaster, J. Flamm, M. Flamm, A. Mayer, G. Donner, S. Oberleitner, L. Havelec, L. Lepsinger and H. Ludwig

Humoral immune response to polymorphic epithelial mucin (*MUC-1*) in patients with benign and malignant breast tumours 1325
S. von Mensdorff-Pouilly, M.M. Gourevitch, P. Kenemans, A.A. Verstraeten, S.V. Litvinov, G.J. van Kamp, S. Meijer, J. Vermorken and J. Hilgers

Early identification of neutropenic patients at risk of gram-positive bacteraemia and the impact of empirical administration of vancomycin 1332
E.C. Dompeling, J.P. Donnelly, S.C. Deresinski, R. Feld, E.F. Lane-Allman and B.E. De Pauw for The Intercontinental Antimicrobial Study Group

Is there a role for melatonin in the treatment of neoplastic cachexia? 1340
P. Lissoni, F. Paolorossi, G. Tancini, S. Barni, A. Ardizzoia, F. Brivio, B. Zubelewicz and V. Chatikhine

Attitudes toward informing the cancer patient—a survey of Norwegian physicians 1344
J.H. Loge, S. Kaasa, Ø. Ekeberg, E. Falkum and K. Hytten

Human papilloma virus has no prognostic significance in cervical carcinoma 1349
G.B. Kristensen, F. Karlsen, A. Jenkins, J. Kærn, V.M. Abeler and C.G. Tropé

Paediatric Oncology

Health-related quality of life of adults surviving malignancies in childhood 1354
M. Apajasalo, H. Sintonen, M.A. Siimes, L. Hovi, C. Holmberg, H. Boyd, A. Mäkelä and J. Rautonen

A new germline *TP53* gene mutation in a family with Li–Fraumeni syndrome 1359
B. Dockhorn-Dworniczak, J. Wolff, C. Poremba, K.-L. Schäfer, J. Ritter, F. Gullotta, H. Jürgens and W. Böcker

Cancer Epidemiology and Prevention

Problems related to the coding of multiple primary cancers 1366
E. Crocetti, S. Lecker, E. Buiatti and H.H. Storm

Experimental Oncology

Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 Workshop 1371
Th.J. Benraad, J. Geurts-Moespot, J. Grøndahl-Hansen, M. Schmitt, J.J.T.M. Heuvel, J.H. de Witte, J.A. Foekens, R.E. Leake, N. Brünner and C.G.J. Sweep

Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites 1382
E. Boven, J. de Jong, C.M. Kuiper, A. Bast and W.J.F. van der Vijgh

p53 expression, DNA content and cell proliferation in primary and synchronous metastatic lesions from ovarian surface epithelial–stromal tumours 1388
M.G. Daidone, E. Benini, B. Valentinis, G. Tomasic, G. Bolis, A. Villa and R. Silvestrini

Expression of CD44 isoforms in human skin cancer 1394
J.C. Simon, K.-H. Heider, A. Dietrich, C. Wuttig, E. Schöpf, G.R. Adolf, H. Ponta and P. Herrlich

Augmented expression of *LCK* message directed from the downstream promoter in human colorectal cancer specimens 1401
K. Nakamura, Y. Chijiiwa and H. Nawata

Tumour cell vaccines that secrete interleukin-2 (IL-2) and interferon γ (IFNγ) are recognised by T cells while resisting destruction by natural killer (NK) cells 1408
K.S. Zier and B. Gansbacher

Tumour growth and fetal uptake of amino acids in the pregnant rat 1413
N. Carbó, F.J. López-Soriano and J.M. Argilés

In vitro induction of differentiation by ginsenosides in F9 teratocarcinoma cells 1420
Y.-N. Lee, H.-Y. Lee, H.-Y. Chung, S.-I. Kim, S.-K. Lee, B.-C. Park and K.-W. Kim

Short Communications

Somatostatin receptor imaging in small cell lung cancer 1429
N. Berenger, J.L. Moretti, C. Boaziz, N. Vigneron, J.F. Morere and J.L. Breau

Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group) 1432
Ph. Rougier, C. Van Pottelsberghe, T. Kok, B. Paillot, T. Wagener, J. De Greve, M.C. Fabri, B. Gerard, M. Van Glabbeke, H. Bleiberg and the EORTC-GITCCG

Letters

Letter to the Editor: Prostate cancer. An insight into screening and local treatment 1434
M. Bolla and H. Van Poppel

Male breast cancer: statistical and clinical data for the Maltese population 1435
M. Grixti, M. Dalmas and V. Muscat

High-dose recombinant interleukin-2/verapamil combination in advanced cancer 1436
P. Tagliaferri, P. Correale, M. Mottola, G. de Simone, V. Montesarchio, E. Matano, A. Rea, A. Morabito, M. Famiani, F. Ciardiello, G. Tortora, M. Caraglia, C. Barile, G. Palmieri and A.R. Bianco

Activity of gemcitabine in platinum-resistant ovarian germ cell cancer 1437
K. Maas, T. Daikeler, L. Kanz and C. Bokemeyer

Calendar of Forthcoming Meetings 1439

Information for Authors I

NUMBER 9

Announcement

Editorial Office Relocation 1445

International Cancer News 1447

Editor's Page Announcing "Current Controversies in Cancer" 1453

Editorials

Do we know what's best for prostate cancer? 1455
J. Waxman and H. Pandha

Communication skills: when, not if, to teach 1457
L.G. Walker

Current Controversies in Cancer

Is routine axillary nodal dissection necessary in the treatment of breast cancer? 1460
PRO: I.S. Fentiman
CONTRA: R. Epstein
ARBITER: L. Barr

Special Paper

A realistic clinical perspective of tamoxifen and endometrial carcinogenesis 1464
V.J. Assikis, P. Neven, V.C. Jordan and I. Vergote

Review

Diagnostic and prognostic implications of genetic lesions in non-Hodgkin's lymphoma 1477
G. Gaidano and A. Carbone

Meeting Highlight

Third International Symposium on Hodgkin's Lymphoma in Köln, Germany 1483
A. Engert, K. Reuß, H. Tesch and V. Diehl

Clinical Oncology

Helping health professionals involved in cancer care acquire key interviewing skills—the impact of workshops 1486
P. Maguire, K. Booth, C. Elliott and B. Jones

The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysis 1490
E. van der Wall, C.C.E. Schaake-Koning, N. van Zandwijk, J.W. Baars, J.H. Schornagel, D.J. Richel, E.J.T. Rutgers, J.H. Borger, J.H. Beijnen and S. Rodenhuis

Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC phase III trial 1498
P.E. Postmus, G. Scagliotti, H.J.M. Groen, F. Gozzelino, J.Th.W. Burghouts, D. Curran, T. Sahmoud, A. Kirkpatrick, G. Giaccone and T.A.W. Splinter

The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: an investigation of their expression as prognostic markers 1504
I. Takanami, F. Tanaka, T. Hashizume, K. Kikuchi, Y. Yamamoto, T. Yamamoto and S. Kodaira

Treatment costs in Hodgkin's disease: a cost-utility analysis 1510
J. Norum, V. Angelsen, E. Wist and J.A. Olsen

Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9 1518
H.L. McLeod, M.A. Graham, S. Aamdal, A. Setanoians, Y. Groot, B. Lund on behalf of the EORTC Early Clinical Trials Group

Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy 1523
A.A. Fauser, B. Duclos, A. Chemaissani, A. Del Favero, F. Cognetti, E. Diaz-Rubio, H. Cortes-Funes, P.F. Conte, H. Dressler on behalf of the European Dolasetron Comparative Study Group

A phase II study of dacarbazine, cisplatin, interferon-α and high-dose interleukin-2 in 'poor-risk' metastatic melanoma 1530
T.M. Proebstle, C. Scheibenbogen, W. Sterry and U. Keilholz

Suramin-induced neutropenia 1534
N.A. Dawson, R.M. Lush, S.M. Steinberg, A.C. Tompkins, D.J. Headlee and W.D. Figg

Paediatric Oncology

Review
Screening for neuroblastoma: 20 years and still no answer 1540
A.W. Craft and L. Parker

Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations 1544
J. Boos, G. Werber, E. Ahlke, P. Schulze-Westhoff, U. Nowak-Göttl, G. Würthwein, F.J. Verspohl, J. Ritter and H. Jürgens

Cancer Epidemiology and Prevention

An analysis of alternative classification schemes for medical atlas mapping 1551
E.K. Cromley and R.G. Cromley

Experimental Oncology

The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters 1560
V. Kuenen-Boumeester, T.H. Van der Kwast, C.C. Claassen, M.P. Look, G.S. Liem, J.G.M. Klijn and S.C. Henzen-Logmans

Multiple forms of TGF-β_1 in breast tissues: a biologically active form of the small latent complex of TGF-β_1 1566
R. Baillie, R.C. Coombes and J. Smith

Pharmacological studies with Cetrorelix (SB-75), a potent antagonist of luteinising hormone-releasing hormone 1574
Th. Reissmann, Th. Klenner, W. Deger, P. Hilgard, G.P. McGregor, K. Voigt and J. Engel

Effect of regional angiotensin II infusion on the relationship between tumour blood flow and fluorouracil uptake in a liver metastasis animal model 1580
M.J. Dworkin, J. Zweit, P. Carnochan, B. Deehan and T.G. Allen-Mersh

pS2 protein expression in gastric carcinoma. An immunohistochemical and immunoradiometric study 1585
J.-C. Machado, F. Carneiro, P. Ribeiro, N. Blin and M. Sobrinho-Simões

Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line 1591
G. Toffoli, G. Corona, M. Gigante and M. Boiocchi

Expression of the 67 kD laminin receptor in human ovarian carcinomas as defined by a monoclonal antibody, MLuC5 1598
F.A. van den Brûle, V. Castronovo, S. Ménard, R. Giavazzi, M. Marzola, D. Belotti and G. Taraboletti

Modulation of [5-^{125}I]iododeoxyuridine incorporation into tumour and normal tissue DNA by methotrexate and thymidylate synthase inhibitors 1603
J. Mester, K. DeGoeij and M. Sluyser

Short Communications

Effects of interleukin-1α on ovarian carcinoma in patients with recurrent disease 1609
C.F. Verschraegen, A.P. Kudelka, W. Termrungruanglert, C.G. de Leon, C.L. Edwards, R.S. Freedman, J.J. Kavanagh and S. Vadhan-Raj

The impact of a psychological intervention on quality of life in non-metastatic breast cancer 1612
G. Marchioro, G. Azzarello, F. Checchin, M. Perale, R. Segati, E. Sampognaro, F. Rosetti, A. Franchin, G.L. Pappagallo and O. Vinante

Letters

Letters to the Editor: Comments on *A Case of Radiation Myelopathy After 2 × 8.5 Gy for Inoperable Non-small Cell Lung Cancer*, Dardoufas *et al.*, *European Journal of Cancer*, 31A, Nos 13/14, pp. 2418–2419, 1995 1616
(i) *M. Hocking*
(ii) *F. Macbeth*

Breast metastases of Merkel cell carcinoma 1617
T. Schnabel and M. Glag

Myocardial infarction associated with vinorelbine (Navelbine^{R}) 1618
A. Zabernigg and C. Gattringer

Calendar of Forthcoming Meetings I

Information for Authors VII

NUMBER 10

International Cancer News 1621

Editorials

Detection of early micrometastases in malignant melanoma 1627
E.M. Rankin

Rheumatoid arthritis and lymphatic cancer 1630
G.J. Macfarlane and R.J. Black

Current Controversies in Cancer

Is isolated limb perfusion of metastatic malignant melanoma of the extremity worthwhile? 1633
Pro: H. Schraffordt Koops
Contra: C. Garbe
Arbiter: P. Hohenberger

Point of View

Primary treatment in stage II non-seminomatous germ cell tumours of the testis: a matter of scalpel or drug infusion? 1641
S. Culine and J.-P. Droz

Special Paper

Early detection of familial ovarian cancer 1645
A. Dørum, G.B. Kristensen, V.M. Abeler, C.G. Tropé and P. Møller

Review

Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? 1652
S.S. Bielack, R. Erttmann, B. Kempf-Bielack and K. Winkler

Meeting Highlight

Diagnostic PCR in melanoma, methods and quality assurance, Epalinges, Switzerland, 26/27 January 1996 1661
U. Keilholz for the EORTC Melanoma Cooperative Group (Immunotherapy Subgroup)

Clinical Oncology

Detection of early micrometastases in subcutaneous fat of primary malignant melanoma patients by identification of tyrosinase-mRNA 1664
T.M. Proebstle, R. Huber and W. Sterry

A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb 1668
M.K. Lingam, D.S. Byrne, T. Aitchison, R.M. MacKie and A.J. McKay

Pain and discomfort during mammography 1674
A.R. Aro, P. Absetz-Ylöstalo, T. Eerola, M. Pamilo and J. Lönnqvist

Prognostic value of quantitative cytometry in a series of 415 T1T2/N0N1/M0 breast cancer patients—preliminary results 1680
M. Bolla, D. Seigneurin, P. Winckel, J. Marron-Charrière, M.H. Panh, D. Pasquier, M. Chédin, R. Payan, F. Merlin and M. Colonna

Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas 1686
K. Weber-Chappuis, S. Bieri-Burger and J. Hurlimann

Large core biopsy for diagnostic and prognostic evaluation of invasive breast carcinomas 1693
C. Di Loreto, F. Puglisi, G. Rimondi, C. Zuiani, G. Anania, V. Della Mea, and C.A. Beltrami

Correlation between P450 CYP1A1 inducibility, MspI genotype and lung cancer incidence 1701
M. Jacquet, V. Lambert, E. Baudoux, M. Muller, P. Kremers and J. Gielen

Enhanced acute toxicity in oropharynx carcinoma treated with radiotherapy and concomitant cisplatin, 5-fluorouracil and mitomycin C 1707
C. Berger, S. Chapet, A. Reynaud-Bougnoux, G. Garand, O. Le Floch and G. Calais

Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer 1712
F. Otto, P. Schmid, A. Mackensen, U. Wehr, A. Seiz, M. Braun, C. Galanos, R. Mertelsmann and R. Engelhardt

Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies 1719
P. Comella, G. Palmieri, V. Lorusso, G. Catalano, D. Nicollela, G.P. Ianniello, R. Casaretti, M. Montella, G. Frasci, M. Perna and G. Comella

Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin 1727
F.A.N. Zoetmulder and P.H. Sugarbaker

Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration 1734
B. Desoize, G. Berthiot, L. Manot, P. Coninx and P. Dumont

Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients 1739
J. Aparicio, A. Oltra, C. Llorca, J. Montalar, C. Herranz, J. Gómez-Codina, M. Pastor and B. Munárriz

Paediatric Oncology

An increased loading dose of ondansetron: a North European, double-blind randomised study in children, comparing 5 mg/m^2 with 10 mg/m^2 1744
P. Brock, B. Brichard, C. Rechnitzer, N.E. Langeveld, M. Lanning, S. Söderhäll and C. Laurent

Constitutional nonsense germline mutations in the *RB1* gene detected in patients with early onset unilateral retinoblastoma 1749
J.K. Cowell and H. Cragg

Cancer Epidemiology and Prevention

Rheumatoid arthritis and cancer risk 1753
L. Mellemkjær, M.S. Linet, G. Gridley, M. Frisch, H. Møller and J.H. Olsen

Experimental Oncology

Adaptation of the Cellscan technique for the SCM test in breast cancer 1758
H. Rahmani, M. Deutsch, I. Ron, S. Gerbat, R. Tirosh, A. Weinreb, S. Chaitchik and S. Lalchuk

Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines 1766
N. Zaffaroni, L. Orlandi, D. Gornati, C. De Marco, M. Vaglini and R. Silvestrini

Improved efficacy of chemotherapy by parvovirus-mediated sensitisation of human tumour cells 1774
P. Klein-Bauernschmitt, M. von Knebel Doeberitz, M. Ehrbar, K. Geletneky, J. Kleinschmidt and J.R. Schlehofer

High molecular weight phospholipase A_2 and fatty acids in human colon tumours and associated normal tissue 1781
A.S. Soydan, I.A. Tavares, P.K. Weech, N.M. Tremblay and A. Bennett

Alteration in mucin gene expression and biological properties of HT29 colon cancer cell subpopulations 1788
H. Kitamura, M. Cho, B.H. Lee, J.R. Gum, B.B. Siddiki, S.B. Ho, N.W. Toribara, T. Lesuffleur, A. Zweibaum, Y. Kitamura, S. Yonezawa and Y.S. Kim

Allele loss on chromosome 11q and microsatellite instability in malignant melanoma 1797
I.P.M. Tomlinson, N.E. Beck and W.F. Bodmer

Effects of chronic administration of *N*-(4-hydroxyphenyl)retinamide (4-HPR) in rats on vitamin A metabolism in the eye 1803
K.C. Lewis, L.A. Zech and J.M. Phang

Short Communications

Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients 1809
A. Veronesi, D. Crivellari, M.D. Magri, G. Cartei, M. Mansutti, S. Foladore and S. Monfardini

Soft tissue sarcomas in HIV-infected adult patients 1812
K. Fizazi, J. Feuillard, A. Le Cesne, P. Terrier, M. Raphael, P. Pouillart and T. Tursz

Modulation of toxicity following external beam irradiation preceded by high-dose rate brachytherapy in inoperable oesophageal cancer 1815
B.G. Taal, B.M.P. Aleman, C.C.E. Koning and H. Boot

Letters

Type C hepatitis and chronic lymphocytic leukaemia 1819
L. La Civita, A.L. Zignego, M. Monti, G. Longombardo, F. Greco, G. Pasero and C. Ferri

Angiosarcoma of the breast after conservative surgery and radiation therapy for breast carcinoma: three new cases 1820
J.L. Molitor, M. Spielmann and G. Contesso

Severe cutaneous reactions following interferon injections 1821
M. Azagury, C. Pauwels, S. Kornfeld, N. Bataille and G. Perie

Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma 1822
N. Gebbia and V. Gebbia

Serum neuron-specific enolase (NSE) as a tumour marker for the Ewing's sarcoma family of tumours 1823
K. Fizazi, A. Le Cesne, N. Dohollou, S. Affaied, M. Spielmann and T. Le Chevalier

Transaxillary access to perform hepatic artery infusion (HAI) for secondary or primitive hepatic tumours 1824
C. Zanon and M. Grosso

Calendar of Forthcoming Meetings I

Information for Authors V

NUMBER 11

International Cancer News 1827

Editorial

Bioreductive agents, hypoxic cells and therapy 1833
T. A. Connors

Current Controversies in Cancer

Is mass screening for breast cancer cost-effective? 1835
Pro: H.J. de Koning
Contra: J.W.W. Coebergh
Arbiter: J.A. van Dongen

Point of View

Mixing anthracyclines and radiotherapy in early breast cancer: how safe is it? 1845
P. HjiYiannakis and J.R. Yarnold

Special Paper

The marriage of pathology and genetics in soft tissue tumours: EACR—Mühlbock Memorial Lecture 1849
H. Van den Berghe

Review

Transcription factors as drug targets in cancer 1857
H.C. Hurst

Meeting Highlight

In the shadow of Chernobyl—A report of the First International Conference of the European Commission, Belarus, Russian Federation and Ukraine on the radiological consequences of the Chernobyl accident, 18–22 March 1996, Minsk, Belarus 1864
H.H. Storm

Clinical Oncology

Comparison of the surgical procedures for breast conserving treatment of early breast cancer in seven EORTC centres 1866
M.R. Christiaens, L. Cataliotti, I. Fentiman, E. Rutgers, M. Blichert-Toft, J.E. DeVries, H.P. Graversen, K. Vantongelen and R. Aerts

Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC breast group study 1876
E. Tomiak, M. Piccart, F. Mignolet, T. Sahmoud, R. Paridaens, M. Nooy, L. Beex, I.S. Fentiman, A. Muller, E. van der Schueren and R.D. Rubens on behalf of the EORTC Breast Cancer Cooperative Group

A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer 1888
N.S.A. Stuart, J. Warwick, G.R.P. Blackledge, D. Spooner, C. Keen, A.R. Taylor, C. Tyrell, D.J.T. Webster and H. Earl

Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung 1893
O. Brodin, E. Nou, C. Mercke, C.J. Lindén, R. Lundström, Å. Arwidi, J. Brink and U. Ringborg for the Swedish Lung Cancer Study Group

Accelerated split-course (type B) thoracic radiation therapy plus vinorelbine/carboplatin combination chemotherapy in stage III inoperable non-small cell lung cancer 1901
R. V. Iaffaioli, F. Caponigro, A. Tortoriello, G. Facchini, V. Ravo, M. Maccauro, P. Dimitri, F. Crovella and P. Muto

Phase I/II trial of autologous activated macrophages in advanced colorectal cancer 1905

J.C. Eymard, M. Lopez, A. Cattan, O. Bouché, J.C. Adjizian and J. Bernard

Development of an EORTC questionnaire module to be used in quality of life assessment for patients with oesophageal cancer 1912

J.M. Blazeby, D. Alderson, K. Winstone, R. Steyn, E. Hammerlid, J. Arraras and J.R. Farndon on behalf of the EORTC Quality of Life Study Group

Multivariate analysis of prognostic factors in 106 patients with malignant glioma 1918

E. Salminen, J.M. Nuutinen and S. Huhtala

Combined diagnostic imaging with ^{131}I-metaiodobenzylguanidine and ^{111}In-pentetreotide in carcinoid tumours 1924

B.G. Taal, C.A. Hoefnagel, R.A. Valdés Olmos and H. Boot

A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer 1933

M. Ychou, C. Astre, Ph. Rouanet, J.M. Fabre, B. Saint-Aubert, J. Domergue, D. Ribard, A.J. Ciurana, Ch. Janbon and H. Pujol

Paediatric Oncology

High-dose melphalan followed by autograft employing non-cryopreserved peripheral blood progenitor cells in children 1938

N. Jones, D. Williams, V. Broadbent, K. Jestice, P. Boraks, M. Scott, S. Ager and R. Marcus

Childhood leukaemia and exposure to pesticides: results of a case–control study in Northern Germany 1943

R. Meinert, P. Kaatsch, U. Kaletsch, F. Krummenauer, A. Miesner and J. Michaelis

Epidemiology and Cancer Prevention

Review

An improved statistical approach: can it clarify the role of new prognostic factors for breast cancer? 1949

J.W. Chapman, D. Murray, D.R. McCready, W. Hanna, H.J. Kahn, H.L.A. Lickley, M.E. Trudeau, B.G. Mobbs, C.A. Sawka, E.B. Fish and K.I. Pritchard

Clinical features, frequency and prognosis of Dukes' A colorectal carcinoma: a population-based investigation 1957

C. Di Gregorio, R. Fante, L. Roncucci, M.G. Tamassia, L. Losi, P. Benatti, M. Pedroni, A. Percesepe, S. De Pietri and M. Ponz de Leon

Experimental Oncology

Prognostic significance of p53 nuclear and cytoplasmic overexpression in right and left colorectal adenocarcinomas 1963

X.-F. Sun, J.M. Carstensen, H. Zhang, G. Arbman and B. Nordenskjöld

Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer *in vivo* and *in vitro* 1968
M.H. Seelig and M.R. Berger

Epidermal growth factor (EGF) increases the *in vitro* invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704 1977
J.T. Price, H.M. Wilson and N.E. Haites

Evidence that cisplatin induces serotonin release from human peripheral blood mononuclear cells and that methylprednisolone inhibits this effect 1983
G. Mantovani, A. Macciò, S. Esu and P. Lai

^{211}At-methylene blue for targeted radiotherapy of disseminated melanoma: microscopic analysis of tumour versus normal tissue damage 1986
E.M. Link, A.S. Michalowski and F. Rösch

Capsaicin inhibits plasma membrane NADH oxidase and growth of human and mouse melanoma lines 1995
D.J. Morré, E. Sun, C. Geilen, L.-Y. Wu, R. de Cabo, K. Krasagakis, C.E. Orfanos and D.M. Morré

Amplification of *ERBB* oncogenes in squamous cell carcinomas of the head and neck 2004
J.P. Rodrigo, S. Ramos, P.S. Lazo, I. Alvarez and C. Suárez

In vitro and *in vivo* characterisation of low-resistant mouse reticulosarcoma (M5076) sublines obtained after pulse and continuous exposure to cisplatin 2011
G. Belvedere, L. Imperatori, G. Damia, G. Tagliabue, C. Meijer, E.G.E. de Vries and M. D'Incalci

Short Communications

EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group 2019
L.Y. Dirix, F. Tonnesen, J. Cassidy, R. Epelbaum, W.W. ten Bokkel Huinink, N. Pavlidis, R. Sorio, T. Gamucci, I. Wolff, A. Te Velde, J. Lan and J. Verweij

Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer 2023
C. Tempfer, A. Lösch, H. Heinzl, G. Häusler, E. Hanzal, H. Kölbl, G. Breitenecker and Ch. Kainz

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma 2026
A.S.T. Planting, M.E.L. van der Burg, S.H. Goey, J.H.M. Schellens, Ch. Vecht, M. de Boer-Dennert, G. Stoter and J. Verweij

Letters

Letters to the Editor: Comments on *Does Age at Last Birth Affect Breast Cancer Risk?*, Hsieh *et al.*, *European Journal of Cancer*, 32A, No. 1, pp. 118–121, 1996 2029
(i) *A. Maguire and A. Kalache*
(ii) *Response from C.-C. Hsieh et al.*

Letters to the Editor: Comments on *Palliative Endoscopic Therapy of Rectal Carcinoma*, Dohmoto *et al.*, *European Journal of Cancer*, 32A, No. 1, pp. 25–29, 1996 2031
(i) *R. Glynne-Jones and P.J. Hoskin*
(ii) *J.-F. Bosset, J.-J. Pavy, V. Magnin, H.P. Hamers and J.-C. Horiot*

Calendar of Forthcoming Meetings I

Information for Authors V

NUMBER 12

International Cancer News 2033

Editorial

Cancer and the mind—do we still believe Galen? 2041
F. Stiefel and P. Guex

Review

The diagnostic information of tests for the detection of cancer: the usefulness of the likelihood ratio concept 2042
R.W.M. Giard and J. Hermans

Clinical Oncology

Life events and the risk of breast cancer: a case–control study 2049
A. Ginsberg, S. Price, D. Ingram and E. Nottage

Pyridinium cross-links in multiple myeloma: correlation with clinical parameters and use for monitoring of intravenous clodronate therapy—a pilot study of the German Myeloma Treatment Group (GMTG) 2053
D. Peest, H. Deicher, W. Fett, P. Harms, H.J. Braun, M. Planker, U. Kindler, C. Klinkenstein, E. Schäfer, K. Schumacher and H. Siecke

High-dose melphalan with re-infusion of unprocessed, G-CSF-primed whole blood is effective and non-toxic therapy in multiple myeloma 2058
G.J. Ossenkoppele, G.J. Schuurhuis, A.R. Jonkhoff, K.G. van der Hem, M.C.J.C. Legdeur, A. Boot-Bakker, A.H. Westra, A.M. Dräger and P.C. Huijgens

Pre-operative chemoradiotherapy in non-small cell lung cancer stage III patients. Feasibility, toxicity and long-term results of a phase II study 2064
A. Favaretto, A. Paccagnella, L. Tomio, F. Sartori, A. Cipriani, R. Zuin, L. Reffosco, F. Calabro', F. Rea, C. Ghiotto, V. Chiarion-Sileni, F. Oniga, L. Loreggian and M.V. Fiorentino

A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer 2070
S. Fujino, T. Enokibori, N. Tezuka, Y. Asada, S. Inoue, H. Kato and A. Mori

No age limit for radical radiotherapy in head and neck tumours 2075
T. Pignon, J.-C. Horiot, W. Van den Bogaert, M. Van Glabbeke and P. Scalliet

A comparison of dosimetric methods in isolated limb perfusion with melphalan for malignant melanoma of the lower extremity 2082
D.S. Byrne, A.J. McKay, R. Blackie and R.M. MacKie

Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer 2088
M.-E. Toubert, J. Guillet, M. Chiron, P. Meria, C. Role, M.-H. Schlageter, H. Francois, C. Borschneck, F. Nivelon, F. Desgrandchamps, D. Rastel, O. Cussenot, P. Teillac, A. Le Duc and Y. Najean

Paediatric Oncology

Review Fibromatosis and fibrosarcoma in infancy and childhood 2094
C. Fisher

Time course of methotrexate polyglutamate formation and degradation in the pre-B-leukaemia cell line Nalm6 and in lymphoblasts from children with leukaemia 2101
B. Buchholz, E. Frei, J. Eisenbarth, M. Weigand and R. Ludwig

Epidemiology and Cancer Prevention

Alcohol and breast cancer in the Swiss Canton of Vaud 2108
F. Levi, C. Pasche, F. Lucchini and C. La Vecchia

Survival in small intestinal adenocarcinoma 2114
N. Zar, L. Holmberg, E. Wilander and J. Rastad

Experimental Oncology

Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue 2120
P.C. Gordge, M.J. Hulme, R.A. Clegg and W.R. Miller

Induction of metalloproteinase (MMP1) expression by epidermal growth factor (EGF) receptor stimulation and serum deprivation in human breast tumour cells 2127
J.E. Nutt and J. Lunec

Rapid recovery of a functional MDR phenotype caused by MRP after a transient exposure to MDR drugs in a revertant human lung cancer cell line 2136
R. Gonzalez Manzano, C. Versanvoort, K. Wright and P.R. Twentyman

Detection of interleukin-8 mRNA and protein in human colorectal carcinoma cells 2142
R. Brew, S.A. Southern, B.F. Flanagan, I.W. McDicken and S.E. Christmas

The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line 2148
P.G. Johnston, F. Geoffrey, J. Drake, D. Voeller, J.L. Grem and C.J. Allegra

Human antibodies against the polymorphic epithelial mucin in ovarian cancer patients recognise a novel sequence in the tandem repeat region 2155
C. Petrarca, A. Rughetti, H. Rahimi, F. D'Agostini, V. Turchi, C. Apollonj Ghetti, G. Scambia, L. Frati and M. Nuti

Tunicamycin potentiates drug cytotoxicity and vincristine retention in multidrug resistant cell lines 2164
D. Hiss, G. Gabriels, P. Jacobs and P. Folb

Short Communications

Possible deleterious effect of tamoxifen in premenopausal women with locoregional recurrence of breast cancer 2173
M.M. Borner, M. Bacchi and M. Castiglione

Interstitial pneumopathy after mantle field irradiation for Hodgkin's disease 2177
H. Pape, A. Mulhern, J.v.d. Haar, I. Ernst, U. Göbel and G. Schmitt

Letters

Letters to the Editor: Comments on *The Role of Reproductive and Menstrual Factors in Cancer of the Breast Before and After Menopause*, Talamini *et al.*, *Eur J Cancer*, 32A, No. 2, pp. 303–310, 1996 2181
(i) *L. Berstein*
(ii) Response from: *S. Franceschi, R. Talamini and C. La Vecchia*

$p21^{WAF1}$ and p53 immunohistochemical expression in breast carcinoma may predict therapeutic response to adjuvant treatment 2182
M. Barbareschi, C. Doglioni, S. Veronese, M. Bonzanini, P. Dalla Palma, A.L. Harris and O. Caffo

Is the time interval between diagnosis and radiation treatment an important factor in brain metastases? 2184
I. Henríquez, C. Conill, E. Verger and F. Graus

Malignant lymphoma with severe hypoglycaemia 2185
C. Camci, S. Paydaş, B. Şahin and E. Coşar

Calendar of Forthcoming Meetings I

NUMBER 13

International Cancer News — 2187

Editorial

Chemotherapy of high-grade gliomas: beginning of a new era or the end of the old? — 2193
M. Brada and G. Sharpe

Current Controversies in Cancer

Is intra-arterial chemotherapy worthwhile in the treatment of patients with unresectable hepatic colorectal cancer metastases? — 2195
Pro: A.M. Cohen and N.E. Kemeny
Contra: C.-H. Köhne and J. Wils
Arbiter: P.G. de Takats and D.J. Kerr

Point of View

Inheritance and susceptibility to tumours of the large bowel: a new classification of colorectal malignancies — 2206
M. Ponz de Leon, P. Benatti and L. Roncucci

Review

Intra-epithelial and invasive cervical neoplasia during HIV infection — 2212
M. Boccalon, U. Tirelli, F. Sopracordevole and E. Vaccher

Meeting Highlight

Sixth Charles Heidelberger Conference on "Control of Cell Proliferation and Differentiation: Molecular Targets in Carcinogenesis and Cancer Therapy", 9–13 July 1995, Essen, Germany — 2218
M.F. Rajewsky

Clinical Oncology

Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study — 2229
M. Sanson, A. Ameri, A. Monjour, T. Sahmoud, P. Ronchin, M. Poisson and J.Y. Delattre

The Charing Cross Hospital experience with temozolomide in patients with gliomas — 2236
E.S. Newlands, S.M. O'Reilly, M.G. Glaser, M. Bower, H. Evans, C. Brock, M.H. Brampton, I. Colquhoun, P. Lewis, J.M. Rice-Edwards, R.D. Illingworth and P.G. Richards

Demonstration of p53 protein and *TP53* gene mutations in oligodendrogliomas — 2242
C. Hagel, G. Laking, R. Laas, S. Scheil, R. Jung, K. Milde-Langosch and D.K. Stavrou

The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer 2249
W.K. Evans and T. Le Chevalier

Unknown primary carcinoma: randomised studies are needed to identify optimal treatments and their benefits 2256
D.C. Farrugia, A.R. Norman, M.C. Nicolson, M. Gore, E.O. Bolodeoku, A. Webb and D. Cunningham

Complications of an implantable venous access device (Port-a-Cath®) during intermittent continuous infusion of chemotherapy 2262
R.L. Poorter, F.N. Lauw, W.A. Bemelman, P.J.M. Bakker, C.W. Taat and C.H.N. Veenhof

Surveillance versus adjuvant chemotherapy in stage I non-seminomatous testicular cancer: a decision analysis 2267
A.M. Stiggelbout, G.M. Kiebert, J.C.J.M. de Haes, H.J. Keizer, G. Stoter, R. de Wit, J.B. Vermorken, J.W.H. Leer and J. Kievit

The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a controlled clinical trial using computerised assessments 2275
L.G. Walker, K.P. Wesnes, S.D. Heys, M.B. Walker, J. Lolley and O. Eremin

Quality of life: perception of lung cancer patients 2284
A. Montazeri, R. Milroy, C.R. Gillis and J. McEwen

Paediatric Oncology

Announcement New section—Paediatric Updates 2290

Review Etoposide for the treatment of paediatric tumours: what is the best way to give it ? 2291
S.P. Lowis and D.R. Newell

Screening for neuroblastoma in late infancy by use of EIA (enzyme-linked immunoassay) method: 115 000 screened infants in Austria 2298
R. Kerbl, C.E. Urban, P.F. Ambros, H. Lackner, R. Ladenstein, E. Spuller, I. Mutz, I. Ambros, G. Amann, H. Gadner and L. Parker

Epidemiology and Cancer Prevention

Primary gastric non-Hodgkin's lymphoma stage IE and IIE 2306
M.L.M. Lybeert, W. De Neve, L.W. Vrints, V. Coen and J.W.W. Coebergh

Experimental Oncology

Tumour necrosis factor and interferon are selectively cytostatic *in vitro* for hormone-dependent and hormone-independent human breast cancer cells 2312
H. Mueller, N. Flury, R. Liu, S. Scheidegger and U. Eppenberger

Analysis of O^6-methylguanine-DNA methyltransferase mRNA in fine needle biopsies from human melanoma metastases by reverse transcription and polymerase chain reaction 2319
J. Hansson, G. Martenhed, S. Egyházi, E. Tani and A. Platz

Cisplatin combined with the new cisplatin–procaine complex DPR: *in vitro* and *in vivo* studies 2327
M. Viale, M.O. Vannozzi, F. Merlo, S. Cafaggi, B. Parodi and M. Esposito

Examination of multidrug resistance in cell lines and primary breast tumours by flow cytometry 2334
I. Brotherick, B.K. Shenton, M. Egan, W.E. Cunliffe, D.A. Browell, L.G. Lunt, J.R. Young and M.J. Higgs

Enhanced invasiveness of tumour cells after host exposure to heavy metals 2342
A. Haga, H. Nagase, H. Kito and T. Sato

Oestrogen and progesterone receptors in gastrointestinal cancer cell lines 2348
E. Jacobs, S.A. Watson, J.D. Hardcastle and J.F.R. Robertson

Short Communications

A pilot study to evaluate paclitaxel (Taxol™) as primary medical treatment for patients with inoperable stage III and IV breast carcinoma 2354
C.N. Rees, D. Sinnett, C. Lowdell, J. English and R.C. Coombes

Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy 2357
D.C. Currow, M. Findlay, K. Cox and P.R. Harnett

Polymorphisms in $P21^{CIP1/WAF1}$ are not correlated with *TP53* status in sporadic ovarian tumours 2360
B.J. Milner, L. Hosking, S. Sun, N.E. Haites and W.D. Foulkes

Letters

Letters to the Editor: Comments on *Prebiopsy Neo-adjuvant Endocrine Therapy for Breast Cancer to Prevent Post-surgery Trauma-induced Growth Factor and Immune-suppression Mediated Tumour Progression*, Oliver *et al.*, *Eur J Cancer*, 32A, No. 3, pp. 396–397, 1996 2364
(i) *K. Mokbel*
(ii) *Response from R.T.D. Oliver*

A phase I/II trial of epirubicin and high dose tamoxifen as a potential modulator of multidrug resistance in advanced hepatocellular carcinoma 2366
M. Raderer, J. Pidlich, C. Müller, F. Pfeffel, G.V. Kornek, M. Hejna and W. Scheithauer

Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients 2368
G. Ferrari and G.V. Scagliotti

Abnormalities of the $P16^{INK4A}$ gene in thyroid cancer cell lines 2369
M. Ivan, D. Wynford-Thomas and C.J. Jones

Lack of carboplatin activity in malignant lymphomas 2370
M. Balzarotti, C. Tondini, V. Bonfante, L. Devizzi, S. Viviani, M. Fornier and A. Santoro

Radon exposure and incidence of paediatric malignancies 2371
R. Thorne, N.K. Foreman and M.G. Mott

Very high male lung cancer incidence in areas with tobacco industries 2372
M.L.G. Janssen-Heijnen, J.W.W. Coebergh and J. van Reek

Correction and Apology

Mixing anthracyclines and radiotherapy in early breast cancer: how safe is it? 2374
P. HjiYiannakis and J.R. Yarnold

Calendar of Forthcoming Meetings I

NUMBER 14

Special Issue: Basic and Clinical Research on Angiogenesis

Guest editors: G. Gasparini and J. Folkman

Overview

Angiogenesis research up to 1996. A commentary on the state of art and suggestions for future studies 2379
G. Gasparini

Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models 2386
D. Hanahan, G. Christofori, P. Naik and J. Arbeit

Tumour suppressor genes and angiogenesis: the role of *TP53* in fibroblasts 2394
V. Stellmach, O.V. Volpert, S.E. Crawford, J. Lawler, R.O. Hynes and N. Bouck

Role of soluble mediators in angiogenesis 2401
F. Bussolino, A. Albini, G. Camussi, M. Presta, G. Viglietto, M. Ziche and G. Persico

Vascular endothelial growth factor 2413
N. Ferrara

Role of integrins in angiogenesis 2423
P.C. Brooks

How the extracellular matrix and macrophages contribute to angiogenesis-dependent diseases 2430
P.J. Polverini

Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis 2438
J. Rak, J. Filmus and R.S. Kerbel

Angiogenesis and metastasis 2451
L.M. Ellis and I.J. Fidler

TNP-470/minocycline/cytotoxic therapy: a systems approach to cancer therapy 2461
B.A. Teicher, Y. Emi, Y. Kakeji and D. Northey

Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor 2467
Ke-Lin, Qu-Hong, J.A. Nagy, I.A. Eckelhoefer, E.M. Masse, A.M. Dvorak and H.F. Dvorak

Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation 2474
P.B. Vermeulen, G. Gasparini, S.B. Fox, M. Toi, L. Martin, P. McCulloch, F. Pezzella, G. Viale, N. Weidner, A.L. Harris and L.Y. Dirix

Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vicenza studies 2485
G. Gasparini

Angiogenesis in primary lung cancer and lung secondaries 2494
F. Pezzella, A. Di Bacco, S. Andreola, A.G. Nicholson, U. Pastorino and A.L. Harris

Prognostic value of angiogenesis in gastro-intestinal tumours 2501
Y.S. Chung, K. Maeda and M. Sowa

Intratumoral vascularity as a prognostic factor in cancers of the urogenital tract 2506
N. Weidner

Clinical significance of the determination of angiogenic factors 2513
M. Toi, T. Taniguchi, Y. Yamamoto, T. Kurisaki, H. Suzuki and T. Tominaga

TNP-470 (AGM-1470): mechanisms of action and early clinical development 2520
V. Castronovo and D. Belotti

Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer 2528
D.C. Talbot and P.D. Brown

New perspectives in clinical oncology from angiogenesis research 2534
J. Folkman

Information for Authors I

SUPPLEMENT 1

Second Educational Convention of the European School of Oncology
Vienna, Austria Center, 27–29 June 1996

SUPPLEMENT 2

7th EORTC Breast Cancer Working Conference
Bordeaux, France, September 10–13 1996

SUPPLEMENT 3

Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation S1
D. Cunningham

Future directions for clinical research with CPT-11 (irinotecan) S9
D. Von Hoff

Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer S13
Y. Shimada, P. Rougier and H. Pitot

Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective S18
H. Bleiberg and E. Cvitkovic

CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer S24
L. Saltz, Y. Shimada and D. Khayat

Information for Authors I

SUPPLEMENT 4

Current approaches in cytoprotection: the role of amifostine (Ethyol®) in altering and ameliorating toxicities in Cancer therapy S1
R.M. Bukowski

The need for cytoprotection S2
R.M. Bukowski

The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol®) S5
R.L. Capizzi

WR-1065, the active metabolite of amifostine (Ethyol®), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells S17
D.S. Alberts, L.A. Speicher, M. Krutzsch, J. Wymer, R.L. Capizzi, J. Conlon, A. Barrett and M. Aickin

Cardioprotection of rat heart myocytes with amifostine (Ethyol®) and its free thiol, WR-1065, *in vitro* S21
R.T. Dorr, K. Lagel and S. McLean

Amifostine (Ethyol®): pharmacokinetic and pharmacodynamic effects *in vivo* S26
W.J.F. van der Vijgh and A.E.C. Korst

The potential role of amifostine (Ethyol®) in haematological malignancies S31
N.C. Gorin

Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol®) S40
L.M. Schuchter

Clinical effects of amifostine (Ethyol®) in patients treated with carboplatin S43
G.T. Budd, R. Ganapathi, R.M. Bukowski and S. Murthy

Amifostine (Ethyol®): dosing, administration and patient management guidelines S46
R.M. Bukowski

SUPPLEMENT 5

Introduction S1
P. Rougier

Colorectal cancer: the challenge S2
H. Bleiberg

Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer: a critical review of comparative studies S7
R. Labianca, A. Pessi, G. Facendola, M. Pirovano and G. Luporini

Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens S13
P. Ross, J. Heron and D. Cunningham

Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents S18
H.-J. Schmoll

A glimpse of the future. New directions in the treatment of colorectal cancer S23
E. Van Cutsem

A retrospective study of resource utilisation in the treatment of advanced colorectal cancer in Europe S28
K. Torfs and S. Pocceschi

Reprinted Paper

'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia I
D. Cunningham, J.R. Zalcberg, U. Rath, I. Olver, E. Van Cutsem, C. Svensson, J.F. Seitz, P. Harper, D. Kerr, G. Perez-Manga, M. Azab, L. Seymour, K. Lowery and the 'Tomudex' Colorectal Cancer Study Group

Information for Authors XIII